IRAK4: potential therapeutic target for airway disease exacerbations

Joseph A. Jude; Reynold A. Panettieri

doi:10.1016/j.tips.2025.01.001

IRAK4: potential therapeutic target for airway disease exacerbations

Joseph A. Jude, Reynold A. Panettieri

Rutgers Institute for Translational Medicine and Science

Research output: Contribution to journal › Short survey › peer-review

Abstract

Inflammatory lung diseases represent a significant healthcare burden. There is an unmet need for identifying therapeutic targets for inflammatory lung diseases, such as asthma, and chronic obstructive pulmonary disease (COPD). In a recent study, Sayers et al. validate the inhibition of interleukin (IL)-1 receptor-associated kinase (IRAK)-4 as a potential therapeutic strategy toward lung inflammation and inflammatory airway diseases more generally.

Original language	English (US)
Pages (from-to)	201-203
Number of pages	3
Journal	Trends in Pharmacological Sciences
Volume	46
Issue number	3
DOIs	https://doi.org/10.1016/j.tips.2025.01.001
State	Published - Mar 2025

All Science Journal Classification (ASJC) codes

Toxicology
Pharmacology

Keywords

COPD
Toll-like receptor, asthma
interleukin-1 receptor-associated kinase 4
lung inflammation

Access to Document

10.1016/j.tips.2025.01.001

Cite this

@article{b277991587f249a793ef69bfc83ddf92,

title = "IRAK4: potential therapeutic target for airway disease exacerbations",

abstract = "Inflammatory lung diseases represent a significant healthcare burden. There is an unmet need for identifying therapeutic targets for inflammatory lung diseases, such as asthma, and chronic obstructive pulmonary disease (COPD). In a recent study, Sayers et al. validate the inhibition of interleukin (IL)-1 receptor-associated kinase (IRAK)-4 as a potential therapeutic strategy toward lung inflammation and inflammatory airway diseases more generally.",

keywords = "COPD, Toll-like receptor, asthma, interleukin-1 receptor-associated kinase 4, lung inflammation",

author = "Jude, {Joseph A.} and Panettieri, {Reynold A.}",

note = "Publisher Copyright: {\textcopyright} 2025 Elsevier Ltd",

year = "2025",

month = mar,

doi = "10.1016/j.tips.2025.01.001",

language = "English (US)",

volume = "46",

pages = "201--203",

journal = "Trends in Pharmacological Sciences",

issn = "0165-6147",

publisher = "Elsevier Ltd",

number = "3",

}

TY - JOUR

T1 - IRAK4

T2 - potential therapeutic target for airway disease exacerbations

AU - Jude, Joseph A.

AU - Panettieri, Reynold A.

PY - 2025/3

Y1 - 2025/3

N2 - Inflammatory lung diseases represent a significant healthcare burden. There is an unmet need for identifying therapeutic targets for inflammatory lung diseases, such as asthma, and chronic obstructive pulmonary disease (COPD). In a recent study, Sayers et al. validate the inhibition of interleukin (IL)-1 receptor-associated kinase (IRAK)-4 as a potential therapeutic strategy toward lung inflammation and inflammatory airway diseases more generally.

AB - Inflammatory lung diseases represent a significant healthcare burden. There is an unmet need for identifying therapeutic targets for inflammatory lung diseases, such as asthma, and chronic obstructive pulmonary disease (COPD). In a recent study, Sayers et al. validate the inhibition of interleukin (IL)-1 receptor-associated kinase (IRAK)-4 as a potential therapeutic strategy toward lung inflammation and inflammatory airway diseases more generally.

KW - COPD

KW - Toll-like receptor, asthma

KW - interleukin-1 receptor-associated kinase 4

KW - lung inflammation

UR - http://www.scopus.com/inward/record.url?scp=85215410614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85215410614&partnerID=8YFLogxK

U2 - 10.1016/j.tips.2025.01.001

DO - 10.1016/j.tips.2025.01.001

M3 - Short survey

C2 - 39824674

AN - SCOPUS:85215410614

SN - 0165-6147

VL - 46

SP - 201

EP - 203

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

IS - 3

ER -

IRAK4: potential therapeutic target for airway disease exacerbations

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this